Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
In this medfyle
In this report of the final pre-specified analyses from the phase III ARCHES trial, mHSPC patients who received enzalutamide plus ADT treatment had a reduced risk of death versus those who received placebo plus ADT. Other efficacy endpoints and safety are also updated.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Expert commentary
About this Medfyle
This Medfyle is provided as a service to healthcare professionals. It has been created from content originally published in the Journal of Clinical Oncology® (JCO), an American Society of Clinical Oncology Journal, through an official agreement with Wolters Kluwer.
The summary content was prepared by Sandy Field for Medfyle, reviewed & approved by Jonathan Shamash, MB ChB, MD, FRCP.
Original article:
Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 May 20;40(15):1616-1622. doi: 10.1200/JCO.22.00193. Epub 2022 Apr 14. PMID: 35420921; PMCID: PMC9113211.
The authors of the original article had no part in the creation of the summary.
All Medfyle content, summaries, expert commentaries and slides are owned by GlobalPort (International) Limited. The original journal articles are an exclusive copyright of the American Society of Clinical Oncology.
